Skip to main content

Advertisement

SpringerLink
Log in

Trends in prostate cancer survival in Spain: results from population-based cancer registries

  • Research Articles
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Introduction

The aim of this study is to analyse the evolution of the survival of patients diagnosed with prostate cancer during the period 1995–2003.

Material and methods

This is a population survival study of incident cases of prostate cancer in four Spanish areas: Basque Country, Girona, Murcia and Navarra. We calculated the relative survival (RS) at 5 years and its 95% confidence intervals using a cohort analysis and adjusted for age. To assess the trend in survival between the periods (1995–1999 and 2000–2003) a Poisson regression model was used, adjusting for age, region and period, obtaining the relative risk of death.

Results

The number of patients diagnosed during the 1995–1999 period was 6493 and 8331 in the period 2000–03. The RS at 5 years adjusted for age increased significantly, from 75.3% (95% CI 73.3–77.2) in the period 1995–99 to 85% (95% CI 83.4–86.4) in the period 2000–03.

Conclusion

In Spain the survival of patients with prostate cancer has increased significantly from 1999 to 2003, probably due to the advancement in diagnosis produced by the opportunistic screening of prostate-specific antigen (PSA). Differences in the dissemination and use of the PSA level could explain the observed geographic differences in the increase of survival. It would be necessary to carry out studies to quantify the produced overdiagnosis by screening with PSA in prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hankey BF, Feuer EJ, Clegg LX et al (1999) Cancer surveillance series: interpreting trends in prostate cancer part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 91:1017–1024

    Article  PubMed  CAS  Google Scholar 

  2. Kvale R, Auvinen A, Adami HO et al (2007) Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst 99:1881–1887

    Article  PubMed  Google Scholar 

  3. Larranaga N, Galceran J, Ardanaz E et al (2010) Prostate cancer incidence trends in Spain before and during the prostate-specific antigen era: impact on mortality. Ann Oncol 21[Suppl 3]:iii83–iii89

    Article  PubMed  Google Scholar 

  4. Potosky AL, Miller BA, Albertsen PC, Kramer BS (1995) The role of increasing detection in the rising incidence of prostate cancer. JAMA 273:548–552

    Article  PubMed  CAS  Google Scholar 

  5. Brenner H, Arndt V (2005) Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: populationbased estimates for the year 2000 by period analysis. J Clin Oncol 23:441–447

    Article  PubMed  Google Scholar 

  6. Borras J, Marcos-Gragera R, Torres A, Espinas JA (2008) [Analysis of cancer incidence, survival and mortality according to the main tumoral localizations, 1985–2019: prostate cancer]. Med Clin (Barc) 131[Suppl 1]:63–66

    Article  Google Scholar 

  7. Galceran J, Puigdefabregas A, Ribas G et al (2008) Cancer survival trends in Catalonia and comparison with Europe. Med Clin (Barc) 131[Suppl 1]:19–24

    Article  Google Scholar 

  8. Etzioni R, Penson DF, Legler JM et al (2002) Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94:981–990

    Article  PubMed  Google Scholar 

  9. Merrill RM, Wiggins CL (2002) Incidental detection of population-based prostate cancer incidence rates through transurethral resection of the prostate. Urol Oncol 7:213–219

    Article  PubMed  Google Scholar 

  10. Baade PD, Youlden DR, Krnjacki LJ (2009) International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 53:171–184

    Article  PubMed  CAS  Google Scholar 

  11. Collin SM, Martin RM, Metcalfe C et al (2008) Prostate-cancer mortality in the USA and UK in 1975–2004: an ecological study. Lancet Oncol 9: 445–452

    Article  PubMed  Google Scholar 

  12. Bray F, Lortet-Tieulent J, Ferlay J et al (2010) Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 46:3040–3052

    Article  PubMed  CAS  Google Scholar 

  13. Cayuela A, Rodriguez-Dominguez S, Martin VE, Candau BR (2008) Recent changes in prostate cancer mortality in Spain. Trends analysis from 1991 to 2005. Actas Urol Esp 32:184–189

    Article  PubMed  CAS  Google Scholar 

  14. Verdecchia A, Guzzinati S, Francisci S et al (2009) Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer 45:1042–1066

    Article  PubMed  Google Scholar 

  15. Chirlaque MD, Salmeron D, Ardanaz E et al (2010) Cancer survival in Spain: estimate for nine major cancers. Ann Oncol 21[Suppl 3]:iii21–iii29

    Article  PubMed  Google Scholar 

  16. Curado MP, Edwards B, Shin HR et al (eds) (2007) Cancer incidence in five continents, vol. IX. IARC, Lyon

    Google Scholar 

  17. Navarro C, Martos C, Ardanaz E et al (2010) Population-based cancer registries in Spain and their role in cancer control. Ann Oncol 21[Suppl 3]:iii3–13

    Article  PubMed  Google Scholar 

  18. Martos MC, Saurina C, Feja C et al (2009) Accurately estimating breast cancer survival in Spain: cross-matching local cancer registries with the National Death Index. Rev Panam Salud Publica 26:51–54

    Article  PubMed  Google Scholar 

  19. Navarro C (2006) The National Death Index: a largely expected advance in the access to mortality data. Gac Sanit 20:421–423

    Article  PubMed  Google Scholar 

  20. Ferlay J, Burkhard S, Whelan S, Parkin DM (2005) Check and conversion programs for cancer registries (IARC/IACR Tools for Cancer Registries in Europe). IARC, Lyon

    Google Scholar 

  21. de Angelis R, Francisci S, Baili P et al (2009) The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis. Eur J Cancer 45:909–930

    Article  PubMed  Google Scholar 

  22. Frit A, Jack A, Percy C et al (2000) International Classification of Diseases for Oncology, 3rd edn. World Health Organisation, Geneva

    Google Scholar 

  23. Cancer Survival Group (2011) Strel Computer Program Version V 6.0 for Cancer Survival Analysis. (7 June 2011, date last accessed)

    Google Scholar 

  24. Esteve J, Benhamou E, Croasdale M, Raymond L (1990) Relative survival and the estimation of net survival: elements for further discussion. Stat Med 9:529–538

    Article  PubMed  CAS  Google Scholar 

  25. Corazziari I, Quinn M, Capocaccia R (2004) Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40:2307–2316

    Article  PubMed  Google Scholar 

  26. Dickman PW, Sloggett A, Hills M, Hakulinen T (2004) Regression models for relative survival. Stat Med 23:51–64

    Article  PubMed  Google Scholar 

  27. Anonymous (2007) StataCorp. Stata Statistical Software: Release 10. StataCorp LP, TX

  28. Sanchez MJ, Payer T, De Angelis R et al (2010) Cancer incidence and mortality in Spain: estimates and projections for the period 1981–2012. Ann Oncol 21[Suppl 3]:iii30–iii36

    Article  Google Scholar 

  29. Welch HG, Schwartz LM, Woloshin S (2000) Are increasing 5-year survival rates evidence of success against cancer? JAMA 283:2975–2978

    Article  PubMed  CAS  Google Scholar 

  30. Draisma G, Etzioni R, Tsodikov A et al (2009) Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 101:374–383

    Article  PubMed  Google Scholar 

  31. Coleman MP, Quaresma M, Berrino F et al (2008) Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 9:730–756

    Article  PubMed  Google Scholar 

  32. Jonler M, Eddy B, Poulsen J (2005) Prostatespecific antigen testing in general practice: a survey among 325 general practitioners in Denmark. Scand J Urol Nephrol 39:214–218

    Article  PubMed  Google Scholar 

  33. Andren O, Garmo H, Mucci L et al (2009) Incidence and mortality of incidental prostate cancer: a Swedish register-based study. Br J Cancer 100:170–173

    Article  PubMed  CAS  Google Scholar 

  34. Bangma CH, Roemeling S, Schroder FH (2007) Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 25:3–9

    Article  PubMed  CAS  Google Scholar 

  35. Flamand V, Zini L, Salleron J et al (2008) Observational survey on variations of prostate cancer incidence by stage in the Nord-Pas-de-Calais region between 1998 and 2004. Prog Urol 18:53–59

    Article  PubMed  CAS  Google Scholar 

  36. Vutuc C, Waldhoer T, Madersbacher S et al (2001) Prostate cancer in Austria: impact of prostate-specific antigen test on incidence and mortality. Eur J Cancer Prev 10:425–428

    Article  PubMed  CAS  Google Scholar 

  37. Sandblom G, Varenhorst E, Rosell J et al (2011) Randomised prostate cancer screening trial: 20 year follow-up. BMJ 342:d1539

    Article  PubMed  Google Scholar 

  38. Pashayan N, Duffy SW, Pharoah P et al (2009) Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. Br J Cancer 100:1198–1204

    Article  PubMed  CAS  Google Scholar 

  39. Schroder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360: 1320–1328

    Article  PubMed  Google Scholar 

  40. Welch HG, Albertsen PC (2009) Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst 101:1325–1329

    Article  PubMed  Google Scholar 

  41. Hugosson J, Carlsson S, Aus G et al (2010) Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11:725–732

    Article  PubMed  Google Scholar 

  42. Harlan LC, Potosky A, Gilliland FD et al (2001) Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst 93:1864–1871

    Article  PubMed  CAS  Google Scholar 

  43. van Leeuwen PJ, Connolly D, Gavin A et al (2010) Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. Eur J Cancer 46:377–383

    Article  PubMed  Google Scholar 

  44. Welch HG, Black WC (2010) Overdiagnosis in cancer. J Natl Cancer Inst 102:605–613

    Article  PubMed  Google Scholar 

  45. Namiki S, Arai Y (2010) Health-related quality of life in men with localized prostate cancer. Int J Urol 17:125–138

    Article  PubMed  Google Scholar 

  46. Ponholzer A, Brossner C, Struhal G et al (2006) Lower urinary tract symptoms, urinary incontinence, sexual function and quality of life after radical prostatectomy and external beam radiation therapy: real life experience in Austria. World J Urol 24:325–330

    Article  PubMed  Google Scholar 

  47. Voerman B, Fischer M, Visser A et al (2006) Health-related quality of life in Dutch men with prostate cancer. J Psychosoc Oncol 24:49–64

    Article  PubMed  Google Scholar 

  48. Johansson JE, Andren O, Andersson SO et al (2004) Natural history of early, localized prostate cancer. JAMA 291:2713–2719

    Article  PubMed  CAS  Google Scholar 

  49. Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095–2101

    Article  PubMed  CAS  Google Scholar 

  50. Esserman L, Shieh Y, Thompson I (2009) Rethinking screening for breast cancer and prostate cancer. JAMA 302:1685–1692

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unitat d’Epidemiologia i Registre de Càncer de Girona (UERCG) Pla Director d’Oncologia Departament de Salut, Institut d’Investigació Biomèdica de Girona (IdIBGi), C/ Carrer del Sol, 15, ES-17004, Girona, Spain

    Rafael Marcos-Gragera

  2. Consortium for Biomedical Research in Epidemiology and Public Health (CIBER de Epidemiología y Salud Pública [CIBERESP]), Madrid, Spain

    Rafael Marcos-Gragera, Diego Salmerón, Eva Ardanaz, Nerea Larrañaga, Carmen Navarro & María-Dolores Chirlaque

  3. Departamento de Ciencias Sociosanitarias, Facultad de Medicina, Murcia, Spain

    Diego Salmerón & Carmen Navarro

  4. Registro de Cáncer de Murcia Servicio de Epidemiología, Consejería de Sanidad, Murcia, Spain

    Diego Salmerón, Carmen Navarro & María-Dolores Chirlaque

  5. Departamento de Enfermería, Universidad de Girona, Girona, Spain

    Rafael Marcos-Gragera & Bernat-Carles Serdà

  6. Departamento Sanidad Gobierno Vasco, Registro de Cáncer de Euskadi, Vitoria-Gasteiz, Spain

    Isabel Izarzugaza

  7. Registro de Cáncer de Navarra, Instituto de Salud Pública de Navarra, Pamplona, Navarra, Spain

    Eva Ardanaz & Erkuden San Román

  8. Registro de Cáncer de Euskadi, Subdirección de Salud Pública de Gipuzkoa, Donostia-San Sebastián, Guipúzcoa, Spain

    Nerea Larrañaga

Authors
  1. Rafael Marcos-Gragera
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Diego Salmerón
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Isabel Izarzugaza
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eva Ardanaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bernat-Carles Serdà
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nerea Larrañaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Erkuden San Román
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Carmen Navarro
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. María-Dolores Chirlaque
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

The affiliations are listed at the end of the article

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marcos-Gragera, R., Salmerón, D., Izarzugaza, I. et al. Trends in prostate cancer survival in Spain: results from population-based cancer registries. Clin Transl Oncol 14, 458–464 (2012). https://doi.org/10.1007/s12094-012-0824-0

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-012-0824-0

Keywords

Search

Navigation